The year in cardiovascular medicine 2020: epidemiology and prevention

█ Current opinion

Authors:
Ramon Estruch^1,2 Luis M Ruilope^3,4,5 Francesco Cosentino^6
1Department of Internal Medicine, Hospital Clínic, IDIBAPS, University of Barcelona, Villarroel, 170. 08036 Barcelona, Spain;
²CIBER Fisiopatología de la Obesidad y la Nutrición, CIBEROBN, Instituto de Salud Carlos III, Madrid, Spain;
³Hypertension Unit and Cardiorenal Translational Laboratory, Research Institute, Hospital Universitario, 12 de Octubre, Madrid, Spain;
⁴CIBER Enfermedades Cardiovasculares, CIBER-CV Hospital Universitario, 12 de Octubre, Avd. de Córdoba s/n. 28041 Madrid, Spain;
⁵Faculty of Sport Sciences, Universidad Europea de Madrid, Madrid, Spain;
⁶Cardiology Unit, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, FE 200, 171 77 Stockholm, Sweden

Summary

Cardiovascular disease (CVD) prevention has been classically divided into primary (aimed to asymptomatic subjects) and secondary (aimed to patients who have
already suffered a cardiovascular event), but currently this classification is considered arbitrary given the overlap observed, for example in diabetic patients. Thus,
prevention measures may be better divided into “prevention at the population level” and “prevention strategies in subjects with high vascular risk” (1–3). Figure 1 summarizes the role of different actors in the prevention of CVD.

ISSUE: CARDIOLOGIA HUNGARICA | 2021 | VOLUME 51, ISSUE 5-6

click here to read the full article

click here to read the pdf

---